[治疗原发性免疫性血小板减少症的新药]
[New drugs for the treatment of primary immune thrombocytopenia].
作者信息
Kashiwagi Hirokazu
机构信息
Osaka Red Cross Blood Center.
Department of Hematology and Oncology, Graduate School of Medicine, The University of Osaka.
出版信息
Rinsho Ketsueki. 2024;65(9):1101-1105. doi: 10.11406/rinketsu.65.1101.
Two thrombopoietin receptor agonists (eltrombopag and romiplostim), rituximab or splenectomy have been recommended for the treatment of glucocorticoid-resistant ITP in Japanese guidelines. In addition, the Syk inhibitor fostamatinib and FcRn inhibitor efgartigimod were approved in Japan for refractory ITP in 2023 and 2024, respectively. Clinical trials have also reported promising results for the new thrombopoietin receptor agonist avatrombopag, the BTK inhibitor rilzabrutinib, and the C1s inhibitor sutimlimab. These developments will usher in a new era in the treatment of ITP.
在日本的指南中，已推荐两种血小板生成素受体激动剂（艾曲泊帕和罗米司亭）、利妥昔单抗或脾切除术用于治疗糖皮质激素抵抗性免疫性血小板减少症（ITP）。此外，脾酪氨酸激酶（Syk）抑制剂福斯替尼和新生儿Fc受体（FcRn）抑制剂艾加莫德分别于2023年和2024年在日本获批用于难治性ITP。临床试验也报告了新型血小板生成素受体激动剂阿伐曲泊帕、布鲁顿酪氨酸激酶（BTK）抑制剂利扎布替尼和补体C1s抑制剂苏替利单抗的良好结果。这些进展将开创ITP治疗的新纪元。
Zotero 插件